Lindahl has acted as legal advisor to SpectraCure as it organises a preferential rights issue of units. SpectraCure intends to use the issue proceeds to fund, among other things, the preparations for and implementation of a phase 3 clinical study, regulatory preparations prior to an FDA application for accelerated approval, and the initiation of new clinical indications.
The subscription period for the rights issue ended on 23 June 2020 and resulted in the issue being fully subscribed to. 69.2 per cent of the units issued were subscribed to on the basis of unit rights, while 30.8 per cent were subscribed to without the support of unit rights, with 23 per cent of those subscribed to by investors in accordance with guarantee commitments. The issue will provide SpectraCure with approximately MSEK 140 before issue expenses.
Subscription to shares on the basis of the warrants will take place during September 2021. Upon full exercise of all warrants within the framework of issued units, SpectraCure may receive an additional MSEK 100 before issue expenses.
SpectraCure AB (publ), listed on the Nasdaq First North Premier Growth Market, is a medtech company which focuses on developing the treatment systems of the future for internal cancer tumours. The company has developed an advanced medical tool based on the IDOSE® software, packaged in the SpectraCure P18 instrument. The tool, together with associated disposable items, enables personalised treatment of internal solid tumours using photodynamic therapy (PDT).
Lindahl’s team consisted of Johan Herrström (responsible partner), Carl-Johan Krusell and Pontus Söderberg. G&W Fondkommission acted as the financial advisor.
